DARATUMUMAB

Search structure
Trade Names:
Synonyms:
Status: Approved (2015)
Entry Type: Antibody
Molecule Category: UNKNOWN
ATC: L01XC24
UNII: 4Z63YK6E0E

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Lymphocyte differentiation antigen CD38 inhibitor DailyMed
Primary Target
CD38

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Multiple Myeloma 4 D009101 ClinicalTrials
Neoplasms 4 D009369 ClinicalTrials
Amyloidosis 3 D000686 ClinicalTrials
Smoldering Multiple Myeloma 3 D000075122 ClinicalTrials
Paraproteinemias 2 D010265 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 D054198 ClinicalTrials
Leukemia, Myeloid, Acute 2 D015470 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 2 D016403 ClinicalTrials
Lymphoma, Mantle-Cell 2 D020522 ClinicalTrials
Colorectal Neoplasms 2 D015179 ClinicalTrials
Lupus Nephritis 2 D008181 ClinicalTrials
Amyloidosis, Familial 2 D028226 ClinicalTrials
Lymphoma 2 D008223 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 2 D015451 ClinicalTrials
Myelodysplastic Syndromes 2 D009190 ClinicalTrials
Waldenstrom Macroglobulinemia 2 D008258 ClinicalTrials
Alzheimer Disease 2 D000544 ClinicalTrials
Plasmacytoma 2 D010954 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 2 D064129 ClinicalTrials
Lupus Erythematosus, Systemic 2 D008180 ClinicalTrials
Purpura, Thrombocytopenic, Idiopathic 2 D016553 ClinicalTrials
POEMS Syndrome 2 D016878 ClinicalTrials
Lymphoma, Follicular 2 D008224 ClinicalTrials
Leukemia, Biphenotypic, Acute 2 D015456 ClinicalTrials
Graft vs Host Disease 1 D006086 ClinicalTrials
Prostatic Neoplasms 1 D011471 ClinicalTrials
Hodgkin Disease 1 D006689 ClinicalTrials
Lymphoma, Non-Hodgkin 1 D008228 ClinicalTrials
Leukemia, Plasma Cell 1 D007952 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 1 D002289 ClinicalTrials
Mycosis Fungoides 1 D009182 ClinicalTrials
Glioblastoma 1 D005909 ClinicalTrials
Carcinoma, Renal Cell 0 D002292 ClinicalTrials

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
18.06
Injury, poisoning and procedural complications
10.76
Respiratory, thoracic and mediastinal disorders
10.54
Immune system disorders
7.73
Investigations
7.28
Blood and lymphatic system disorders
5.74
Infections and infestations
5.38
Nervous system disorders
5.29
Cardiac disorders
4.98
Gastrointestinal disorders
4.36
Vascular disorders
3.78
Musculoskeletal and connective tissue disorders
2.85
Skin and subcutaneous tissue disorders
2.6
Psychiatric disorders
2.25
Metabolism and nutrition disorders
2.03

Cross References

Resources Reference
CAS NUMBER 945721-28-8
ChEMBL CHEMBL1743007
FDA SRS 4Z63YK6E0E
Guide to Pharmacology 7395
CONTENTS